Pregled bibliografske jedinice broj: 1246049
Empirical first-line treatment use and effectiveness trends in Europe in the period 2013- 2020: results from the European registry on H. pylori management (HP-EUREG)
Empirical first-line treatment use and effectiveness trends in Europe in the period 2013- 2020: results from the European registry on H. pylori management (HP-EUREG) // 34th International Workshop on Helicobacter & Microbiota in Inflammation & Cancer
online, 2021. str. 25-27 (poster, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 1246049 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Empirical first-line treatment use and
effectiveness trends in Europe in the period 2013-
2020: results from the European registry on H.
pylori management (HP-EUREG)
Autori
O. P. Nyssen , Á. Pérez-Aísa , D. Vaira , L. Jonaitis , B. Tepes , A. Keco-Huerga , M. Castro- Fernández , A. Lucendo , D. Bordin , N. Brglez Jurecic , L. Vologzhanina, M. Caldas , G. Fadieienko, R. Abdulkhakov, L. Bujanda, M. Leja, M. Romano, S. Georgopoulos, Ante Tonkić, H. Simsek, A. Gasbarrini, G. M Buzas, P. Phull, M. Venerito, P. Malfertheiner, J. Kupčinskas , G. Babayeva, O. Shvets, F. Lerang, R. Marcos Pinto, T. Rokkas, I. Simsek, S. Smith, Y. Niv, D. Lamarque, F. Heluwaert, A. Goldis, W. Marlicz, V. Milivojevic, L. Boyanova, L. Kunovský, V. Lamy, C. Beglinger, P. Bytzer, L. Capelle, I. Puig, F. Mégraud, C. O’Morain, J. P. Gisbert
Kolaboracija
Hp-EuReg Investigators
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
34th International Workshop on Helicobacter & Microbiota in Inflammation & Cancer
/ - , 2021, 25-27
Skup
International Workshop on Helicobacter and Microbiota in Inflammation and Cancer
Mjesto i datum
Online, 18.09.2021. - 18.09.2021
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Helicobacter pylori
Sažetak
Background: The impact of consensus, prescription choices and efficacy trends on clinical practice over time has not been studied in depth. Methods: International multicenter prospective non-interventional registry aimed to evaluate the decisions and outcomes of H. pylori management by European gastroenterologists. All infected adult patients were registered at AEG-REDCap e-CRF up to February 2021. Modified intention-to-treat (mITT) and time trend analyses were performed. Results: So far 29, 634 first-line empirical prescriptions from 31 European countries have been included. Overall, the most common prescribed treatments in the 2013-20 were triple therapies ; however, a shift in antibiotic regimens was identified. Triple therapies decreased from over 50% of prescription in 2013/15 to less than 20% in 2018/20. Non- bismuth concomitant therapy use decreased from 21% in 2013/14 to 13% in 2019/20, while Pylera® increased from 0-1% in 2014/2015 to 19% in 2019/20. An increase in the average duration of treatments from 11 to 13 days in 2013-2020, and of the daily dose of PPI, was identified (No trend was identified (data now shown) ; however, there was an 8% overall improvement in first-line mITT overall effectiveness from 2013 to 2020 (Table 1). Conclusions: European gastroenterological practice is constantly adapting to the newest published evidence and recommendations (reducing the use of triple therapies and increasing the duration of treatment and the dose of PPIs), with a subsequent progressive improvement in overall effectiveness.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
